Shenmai injection (SMI), one of the most popular
herbal preparations, is widely used for the treatment of coronary atherosclerotic cardiopathy and viral
myocarditis. The purpose of this study was to investigate the effect of
Shenmai injection (SMI) on the CYP3A-mediated metabolism of
midazolam (MDZ). The present study demonstrated that SMI could significantly inhibit MDZ 4-hydroxylation but activate its 1'-hydroxylation in human liver microsomes (HLMs), rat liver microsomes (RLM) and recombinant human
CYP3A4 and
CYP3A5. The opposing effect of SMI was characterized by the kinetic change of increasing Vmax/Km for MDZ 1'-hydroxylation and decreasing Vmax/Km for MDZ 4-hydroxylation in HLM and RLM. The presence of SMI enhanced the inhibition of
ketoconazole on MDZ 4-hydroxylation but weakened or reversed its inhibition on MDZ 1'-hydroxylation in HLM. After single or multiple pretreatment with SMI, the ratios of AUC(4-
OH MDZ)/AUC(MDZ) in rats were significantly decreased, while the ratios of AUC(1'-
OH MDZ)/AUC(MDZ) were increased. Among the major components in SMI, total
ginsenoside (TG), ophiopogon total
saponins (
OTS), ophiopogon total
flavone (OTF),
ginsenoside Rd,
ophiopogonin D and ophiopogonone A exhibited significant inhibition on both 4-hydroxylation and 1'-hydroxylation of MDZ in HLM and RLM, while no activation on MDZ metabolism was observed in the presence of these major constituents alone or together. To further explore the responsible components, 3 mL of SMI was loaded on a solid phase extraction (SPE) C18 cartridge and then separated by different concentrations of
methanol. The fractions eluted with 60% and 90%
methanol both showed significant activation on MDZ 1'-hydroxylation in HLM, but the fraction eluted with 30%
methanol had no such effect. The results indicated that the activation of SMI on MDZ 1'-hydroxylation might be mainly resulted from the
lipid-soluble components in SMI.